Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aimmune Therapeutics stock

Own Aimmune Therapeutics stock in just a few minutes.

Posted

Fact checked

Aimmune Therapeutics, Inc is a biotechnology business based in the US. Aimmune Therapeutics shares (AIMT) are listed on the NASDAQ and all prices are listed in US Dollars. Aimmune Therapeutics employs 339 staff and has a trailing 12-month revenue of around USD$575,000.

How to buy shares in Aimmune Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aimmune Therapeutics. Find the stock by name or ticker symbol: AIMT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aimmune Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aimmune Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aimmune Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aimmune Therapeutics share price

Use our graph to track the performance of AIMT stocks over time.

Aimmune Therapeutics shares at a glance

Information last updated 2020-10-20.
52-week range USD$10.09 - USD$37
50-day moving average USD$34.3242
200-day moving average USD$20.2628
Wall St. target price USD$31.28
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.726

Buy Aimmune Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aimmune Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Aimmune Therapeutics under- or over-valued?

Valuing Aimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Aimmune Therapeutics's PEG ratio

Aimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.16. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Aimmune Therapeutics financials

Revenue TTM USD$575,000
Gross profit TTM USD$0
Return on assets TTM -53.24%
Return on equity TTM -149.17%
Profit margin 0%
Book value $2.748
Market capitalisation USD$2.3 billion

TTM: trailing 12 months

Shorting Aimmune Therapeutics shares

There are currently 4.2 million Aimmune Therapeutics shares held short by investors – that's known as Aimmune Therapeutics's "short interest". This figure is 38% down from 6.7 million last month.

There are a few different ways that this level of interest in shorting Aimmune Therapeutics shares can be evaluated.

Aimmune Therapeutics's "short interest ratio" (SIR)

Aimmune Therapeutics's "short interest ratio" (SIR) is the quantity of Aimmune Therapeutics shares currently shorted divided by the average quantity of Aimmune Therapeutics shares traded daily (recently around 4.2 million). Aimmune Therapeutics's SIR currently stands at 0.99. In other words for every 100,000 Aimmune Therapeutics shares traded daily on the market, roughly 990 shares are currently held short.

However Aimmune Therapeutics's short interest can also be evaluated against the total number of Aimmune Therapeutics shares, or, against the total number of tradable Aimmune Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aimmune Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aimmune Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0903% of the tradable shares (for every 100,000 tradable Aimmune Therapeutics shares, roughly 90 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aimmune Therapeutics.

Find out more about how you can short Aimmune Therapeutics stock.

Aimmune Therapeutics share dividends

We're not expecting Aimmune Therapeutics to pay a dividend over the next 12 months.

Aimmune Therapeutics share price volatility

Over the last 12 months, Aimmune Therapeutics's shares have ranged in value from as little as $10.09 up to $37. A popular way to gauge a stock's volatility is its "beta".

AIMT.US volatility(beta: 1.74)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aimmune Therapeutics's is 1.7408. This would suggest that Aimmune Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aimmune Therapeutics overview

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. As of October 9, 2020, Aimmune Therapeutics, Inc. operates as a subsidiary of Société des Produits Nestlé S.A.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site